Arizona Tribune - Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

"Dr. Jaroszeski is recognized globally for his pioneering work in DNA and drug delivery, and we are honored to welcome him to the Aspire team," said Kraig Higginson, Interim CEO of Aspire Biopharma. "He brings extensive experience in medical delivery systems that will be instrumental in advancing Aspire's proprietary sublingual delivery technology. His insight and track record of innovation will play a critical role as we continue to develop and optimize our platform, building on our initial pipeline and extending these benefits to a broader range of generic medicines."

Mark J. Jaroszeski, Ph.D., is Professor of Medical Engineering at the University of South Florida College of Engineering. Dr. Jaroszeski is a leading innovator in developing DNA/drug delivery technologies and methods to treat disease. He was one of the early pioneers performing in vivo electroporation during the early 1990's, and was among the first researchers to develop basic electrodes and pulsing protocols to deliver chemotherapeutic agents to tumors in animal models in vivo, safely and effectively, with very strong anti-tumor effects. His work on the frontiers of DNA/drug delivery over the past 20 years laid the foundation for more than 100 current clinical trials using gene delivery. He holds 34 U.S. patents, 12 of which have been licensed to 7 companies. He is also currently Vice President of Research for EF Therapeutics, Inc., a start-up company focused on DNA delivery and translating it to the human and veterinary clinical markets. He has published 62 articles in peer-reviewed journals, two books and 11 book chapters, and presented at more than 114 conferences worldwide. He serves as a manuscript reviewer for 21 journals, as well as frequent reviewer for the National Institutes of Health. He has organized/chaired seven professional conferences, and is a delegate to the International Bioelectrics Consortium, a collection of research groups from about 15 countries.

About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.
Contact
Brett Maas
Hayden IR: (646) 536-7331
[email protected]

James Carbonara
Hayden IR: (646)-755-7412
[email protected]

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

A.Moore--AT